<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/01E53956-BF13-4C46-88E2-94DD05716E14"><gtr:id>01E53956-BF13-4C46-88E2-94DD05716E14</gtr:id><gtr:name>Centre for Cooperative Research in Biomaterials (CIC BiomaGUNE)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Imaging &amp; Biomedical Engineering</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/01E53956-BF13-4C46-88E2-94DD05716E14"><gtr:id>01E53956-BF13-4C46-88E2-94DD05716E14</gtr:id><gtr:name>Centre for Cooperative Research in Biomaterials (CIC BiomaGUNE)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3ED34B5-76A5-42E4-B75E-2BE513E68328"><gtr:id>C3ED34B5-76A5-42E4-B75E-2BE513E68328</gtr:id><gtr:name>University of Navarra</gtr:name><gtr:address><gtr:line1>Campus Universitario</gtr:line1><gtr:line4>E-31080 Pamplona</gtr:line4><gtr:line5>Navarra</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/714C23EC-52D5-43FA-AE3E-29F3AC63D56C"><gtr:id>714C23EC-52D5-43FA-AE3E-29F3AC63D56C</gtr:id><gtr:firstName>Maite</gtr:firstName><gtr:surname>Jauregui-Osoro</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FG051437%2F1"><gtr:id>C3BFDF8D-5859-4D15-B16A-84512865EF1A</gtr:id><gtr:title>Pretargeting nanoparticle strategies for multimodal imaging of tumours</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>EP/G051437/1</gtr:grantReference><gtr:abstractText>Imaging of diseases inside the body is becoming a very important part of patient management, especially in cancer and heart disease. Imaging can reveal the extent of disease, and measure the response to treatment, without biopsy or surgery. PET scanners, gamma cameras and MRI scanners are all now routine facilities in hospitals. In this project we will prepare a new generation of contrast agents or radioactive tracers that can be injected into the patient, and will migrate through the body to reach the site of disease, where they will bind. Once the tracer molecules have cleared from the rest of the body, the scanner can detect the present of the remaining tracer molecules in the disease site (e.g. tumour) and thus make an image of the location of disease. The project aims to develop a new system for getting the contrast agent into the target tissue, to obtain clearer and more informative images with greater specificity and lower toxicity and radition dose for the patient. The new system will also have the benefit of being more cost-effective because there will be much less complex processing of the radiotracer on the day of use in the hospital. The new system involves first injecting non-radioactive non-contrast particles into the patient. These will locate in the tumour or disease site and clear from the rest of the body. Then a contrast agent or radiotracer is injected which will seek out the particles and bind to them. Because each particle can bind many tracer molecules, more contrast can be delivered to the target in this way. To achieve this we will develop both the particles themselves and a new set of radiotracers and contrast agents to bind to them, for imaging with a PET scanner, gamma camera or MRI scanner. The new system will be applicable in cancer, heart disease and many other conditions. It can be used not only to image disease but also to treat cancer, if the radiotracer is replaced with a more toxic form of radioactivity. Thus the toxic radioactivity will be delivered selectively to the tumour, so that tumour cells can be killed with minimal harm to normal tissues.</gtr:abstractText><gtr:fund><gtr:end>2012-10-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>315135</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre for Cooperative Research in Biomaterials (CIC BiomaGUNE)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Collaboration during the fellowship.</gtr:description><gtr:id>D0450302-A2F2-4545-9E05-4421A565B914</gtr:id><gtr:impact>The outcomes can be seen in the publications section</gtr:impact><gtr:outcomeId>5460997f73c980.11562957-1</gtr:outcomeId><gtr:partnerContribution>I spent 6 months in their facilities and gained experience in nanoparticle research</gtr:partnerContribution><gtr:piContribution>This collaboration resulted in several publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings have been published in scientific journals</gtr:description><gtr:id>5C6C30F2-E972-46B8-A943-BC22247F1F4B</gtr:id><gtr:impactTypes/><gtr:outcomeId>54609b6eef52a9.58218355</gtr:outcomeId></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The grant has explored the potential of nano particles to visualise disease</gtr:description><gtr:exploitationPathways>further work on the project based on our initial results</gtr:exploitationPathways><gtr:id>EA231399-9490-4D40-BC27-37992340000E</gtr:id><gtr:outcomeId>54609c0a2dc227.43665196</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6CB06CB2-7E22-4E1F-A5F2-49717CE1E6B3</gtr:id><gtr:title>Biocompatible inorganic nanoparticles for [18F]-fluoride binding with applications in PET imaging.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d70e1755eb55e866d1a8abfdee5951c"><gtr:id>6d70e1755eb55e866d1a8abfdee5951c</gtr:id><gtr:otherNames>Jauregui-Osoro M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>54609640098370.64814127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED615A51-1B88-478F-8127-1A4F1E97E093</gtr:id><gtr:title>Aluminium hydroxide stabilised MnFe2O4 and Fe3O4 nanoparticles as dual-modality contrasts agent for MRI and PET imaging.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44d9dab61e70273ff24f0435d40e0d3b"><gtr:id>44d9dab61e70273ff24f0435d40e0d3b</gtr:id><gtr:otherNames>Cui X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>56dddd3b74cd50.49598412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C5602C4-FB55-43F8-91B6-2355850523D2</gtr:id><gtr:title>Synthesis, Characterization, and Application of Core-Shell Co0.16Fe2.84O4@NaYF4(Yb, Er) and Fe3O4@NaYF4(Yb, Tm) Nanoparticle as Trimodal (MRI, PET/SPECT, and Optical) Imaging Agents.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44d9dab61e70273ff24f0435d40e0d3b"><gtr:id>44d9dab61e70273ff24f0435d40e0d3b</gtr:id><gtr:otherNames>Cui X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>56dddd167bc2e9.38550700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16F1541B-13AF-4981-883E-9FE4AE938D01</gtr:id><gtr:title>Iron oxide-filled micelles as ligands for fac-[M(CO)3]+ (M = (99m)Tc, Re).</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5358a3f5544827a8cbc11359aba97a8c"><gtr:id>5358a3f5544827a8cbc11359aba97a8c</gtr:id><gtr:otherNames>Gomez Blanco N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>546096a3c7e657.54151841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DDAA38E-A831-45C8-9558-628A5A1FEF64</gtr:id><gtr:title>An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system.</gtr:title><gtr:parentPublicationTitle>Small (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90b2d22156478c70332cbbbe1df637f2"><gtr:id>90b2d22156478c70332cbbbe1df637f2</gtr:id><gtr:otherNames>Cobaleda-Siles M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1613-6810</gtr:issn><gtr:outcomeId>56dde1d4806340.51603966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CED4EBB-3CA7-445E-BD33-DD782084B143</gtr:id><gtr:title>Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [(18)F]-tetrafluoroborate.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cabaac329c401fd7dc62f7277e03e04e"><gtr:id>cabaac329c401fd7dc62f7277e03e04e</gtr:id><gtr:otherNames>Marti-Climent JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dde326e0d1a6.71661307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>367FD3AC-A23B-469C-BA8E-42503F83CE23</gtr:id><gtr:title>QD-filled micelles which combine SPECT and optical imaging with light-induced activation of a platinum(IV) prodrug for anticancer applications.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6351595fb2de7b0a91a90cd9222939e5"><gtr:id>6351595fb2de7b0a91a90cd9222939e5</gtr:id><gtr:otherNames>Maldonado CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>54609700780686.91293547</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/G051437/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>02567418-12CB-462E-9092-530C6E63B359</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Chemical Biology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>